This study will recruit patients who have been diagnosed with acute (within 26 weeks) infection that are also infected with HIV (HIV/HCV coinfection). The goal of this trial is to find out if the treatment duration can be reduced from 12 weeks to 8 weeks in people who are infected with HCV genotype 1 and 4. A total of 80 patients will be enrolled. The drugs being used in this study are Zepatier (grazoprevir plus elbasvir) combined into one pill taken once-a-day.
The study is recruiting people newly with infected hepatitis C to treat them with the combination of sofosbuvir plus ribavirin for a treatment period of 6 weeks. The study is evaluating the safety and effectiveness of sofosbuvir plus ribavirin.
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-CII)
To read the entire clinical trial description, click here…